Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Acq. announced
Director departure
|
|
Acasti Pharma Inc. (ACST)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/11/2023 |
8-K
| Quarterly results |
| 10/10/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 10/06/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 09/27/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/25/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/25/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 08/25/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 08/11/2023 |
8-K
| Quarterly results |
| 08/11/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/24/2023 |
8-K
| Quarterly results |
| 07/18/2023 |
4
| Derby Michael (Director) has filed a Form 4 on Acasti Pharma Inc.|
Txns:
| Granted 12,500 options to buy
@ $2.64, valued at
$33k
|
|
| 07/18/2023 |
4
| Kavuru Vimal (Director) has filed a Form 4 on Acasti Pharma Inc.|
Txns:
| Granted 12,500 options to buy
@ $2.64, valued at
$33k
|
|
| 07/18/2023 |
4
| Olds Donald (Director) has filed a Form 4 on Acasti Pharma Inc.|
Txns:
| Granted 12,500 options to buy
@ $2.64, valued at
$33k
|
|
| 07/18/2023 |
4
| Macdonald R. Loch (Chief Medical Officer) has filed a Form 4 on Acasti Pharma Inc.|
Txns:
| Granted 60,000 options to buy
@ $2.64, valued at
$158.4k
|
|
| 07/18/2023 |
4
| D'Andrea Carrie (VP Clinical Operations) has filed a Form 4 on Acasti Pharma Inc.|
Txns:
| Granted 42,000 options to buy
@ $2.64, valued at
$110.9k
|
|
| 07/18/2023 |
4
| Kumar Amresh (VP Program Management) has filed a Form 4 on Acasti Pharma Inc.|
Txns:
| Granted 42,000 options to buy
@ $2.64, valued at
$110.9k
|
|
| 07/18/2023 |
4
| Kohli Prashant (CEO) has filed a Form 4 on Acasti Pharma Inc.|
Txns:
| Granted 208,334 options to buy
@ $2.64, valued at
$550k
|
|
| 07/07/2023 |
8-K
| Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...|
Docs:
|
"Articles of Amendment Business Corporations Act Québec Enterprise Number: 1160589793 1 Information about the business ACASTI PHARMA INC. Version of the name of the corporation in any other language other than French, if applicable 1 Amendment to Articles 2.1 Amendment to Name 2.2 Other Amendments See Schedule Attached. 2.3. Date and Time of certificate, if applicable Date: July 10, 2023 Time: 12:01 a.m. 2 Correction of Articles 3 Signature Last name and first name of the authorized officer or director: Prashant Kohli Electonic signature of: Prashant Kohli Reserved for the administration Reference number of request: 020200103314688 Numeric designation: LEGAL_1:80872475.2 SCHEDULE TO ARTICLES OF AMENDMENT OF ACASTI PHARMA INC. As of the date of the issuance of a Certificate of Amendme...",
"Acasti Pharma Announces 1-for-6 Reverse Stock Split LAVAL, Québec, July 7, 2023 -- Acasti Pharma Inc. , a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage , today announced that the Company will effect a 1-for-6 reverse split of its issued and outstanding common shares. The reverse stock split will become effective July 10, 2023 at 12:01 a.m. ET. The Company's common shares will trade on a split-adjusted basis on The NASDAQ Capital Market, as of the opening of trading on Monday, July 10, 2023. The new CUSIP number for the Company's common shares will be 00430K865. The reverse stock split is being affected as part of the Company's plan to regain compl..." |
|
| 07/05/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/26/2023 |
3
| Macdonald R. Loch (Chief Medical Officer) has filed a Form 3 on Acasti Pharma Inc. |
| 05/18/2023 |
3
| D'Andrea Carrie (VP Clinical Operations) has filed a Form 3 on Acasti Pharma Inc. |
| 05/18/2023 |
3
| Kumar Amresh (VP Program Management) has filed a Form 3 on Acasti Pharma Inc. |
| 05/11/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 04/05/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/31/2023 |
8-K
| Resignation/termination of a director |
| 03/13/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 02/14/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
10-Q
| Quarterly Report for the period ended December 31, 2022 |
| 01/25/2023 |
8-K
| Other Events Interactive Data |
| 12/28/2022 |
8-K
| Other Events Interactive Data |
| 12/22/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 09/30/2022 |
4
| Kavuru Vimal (Director) has filed a Form 4 on Acasti Pharma Inc.|
Txns:
| Granted 45,000 options to buy
@ $0 |
|
|
|
|